a r t i c l e s the skin of a SCID mouse (primary implant). We inserted cartilage without RASFs under the skin of the contralateral flank. We removed the implants after 60 d for evaluation (Fig. 1a) . RASFs attached to, invaded into and degraded cartilage in the primary implants (Fig. 1b,c) [12] [13] [14] . We observed multiple areas of directed, invasive growth of RASFs into the implanted cartilage as well as perichondrocytic cartilage degradation (Fig. 1b,c) . Invasion and degradation scores are summarized in Table 1 .
RASFs were not only able to invade and degrade coimplanted cartilage; they were also able to migrate to contralaterally implanted human cartilage that had been inserted without RASFs, and they maintained their ability to invade and degrade the cartilage (Fig. 1d) . Invasion and degradation scores at the contralateral side were slightly lower than those of the primary implant, when the primary and contralateral cartilage were implanted simultaneously (Fig. 1b) .
As controls, we used osteoarthritis synovial fibroblasts (OASFs) isolated from osteoarthritis synovium, instead of RASFs, in the primary implant (Fig. 1b, Supplementary Fig. 1 and Table 1 ) or we inserted cartilage without RASFs or OASFs (Fig. 1b and Table 1 ). In both cases, we observed either no or very low invasion in the analyzed implants (Fig. 1b) . The invasion scores obtained with RASFs were significantly higher than the invasion scores obtained using control OASFs (P < 0.001).
To confirm that the invading cells were of human origin and hence that they had migrated through the mouse body, we performed immunohistochemistry to detect mouse-specific or human-specific antigens. The invading cells at the contralateral implant were positive for human vimentin (Fig. 1e) , follistatin ( Supplementary Fig. 1 ) and pro-matrix metalloprotease-13 (proMMP-13) (Fig. 1f) . Mouse interleukin-1 (IL-1) receptor and H-2D d , (the mouse major histocompatibility complex) were not detectable at the invasion zone (Fig. 1g,h and Supplementary Fig. 1 ), confirming that all invading cells were of human origin.
To evaluate the potential influences of the surgical procedure and wound healing on the migratory capability, we implanted the primary RASF-containing implants either 2 weeks before or 2 weeks after the contralateral RASF-free cartilage-sponge complexes. The invasion scores of the RASF-free contralateral implants were significantly lower than the scores of the primary implants when we inserted them 14 d after the primary implants (P < 0.001). In contrast, when we implanted the RASF-free contralateral implants 14 d before the primary implants, the invasion scores in the contralateral side were significantly higher than those in the primary cartilage (P < 0.001).
When we compared the invasion and degradation scores of the RASF-free contralateral implants between both experimental settings, the scores of contralateral implants inserted before the primary cartilage were significantly higher than contralateral implants inserted after the primary cartilage (invasion, P = 2.0 × 10 −12 ; degradation, P = 3.5 × 10 −4 ). We did not observe significant differences between the RASF-containing primary implants between the experimental settings. The invasion and degradation scores are summarized in Table 1 .
These results suggest that vascularization but not wounding or ongoing wound healing may facilitate invasion of RASFs from the primary implant into the contralateral implant. Of note, the scores of the primary or contralateral implants, inserted after 14 d in both experimental settings, were lower than the implants inserted at day 0 as a result of the shorter invasion period.
Injection of RASFs after cartilage implantation
To further analyze the migratory ability of RASFs and to circumvent influences of wounding or wound healing, we injected RASFs subcutaneously (s.c.), intraperitoneally (i.p.) or intravenously (i.v.) 14 d after cartilage implantation. RASF injection by all routes led to the destruction of the implanted cartilage, but cartilage destruction was most severe after subcutaneous or intravenous application (Fig. 2a-d) (e,f) Immunohistochemistry using human-specific antibodies to detect human RASFs in implants. The human origin of invading cells was confirmed by species-specific antibodies against vimentin (e) or proMMP-13 (f) (red arrows). (g) Immunohistochemistry using mouse-specific antibodies to confirm that the cartilage-invading cells are of human and not murine origin. The invasion zone was not stained by antibodies specific to mouse IL-1 receptor, in contrast to mouse vessels (black arrows). (h) Phase contrast microscopy of the unstained invasion zone in g (green arrows).
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volume 15 | number 12 | december 2009 nature medicine a r t i c l e s scores after these injection routes were similar to the scores obtained after simultaneous implantation of cartilage and RASFs ( Table 1) . Destruction of the implanted cartilage was slightly lower after intraperitoneal injection (Fig. 2c,d ). Scores are summarized in Table 1 .
As before, we next evaluated the ability of the injected RASFs to migrate and invade when they were injected either 2 weeks before or 2 weeks after cartilage implantation. The RASFs invaded and degraded the cartilage in both experimental settings (Table 1) , but, as before, scores were higher when cartilage was implanted first. This again suggested that early neovascularization might facilitate RASF migration. We confirmed that neovascularization occurred within the implants by detecting vessel formation by 14 d after implantation and as early as 7 d after implantation (Fig. 2e) .
Role of synovium, chondrocytes and extracellular matrix
To determine whether other human synovial cells and the extracellular matrix influence the migratory potential of RASFs, we implanted complete synovial tissue as a natural source of RASFs at the primary site without cartilage (Fig. 1a) . Simultaneously, we implanted RASF-free cartilage into the contralateral flank. The implantation of whole synovium resulted in the migration of RASFs out of the synovium toward the contralateral cartilage implant in nine out of 15 mice (Fig. 2d,f) . There was an extensive invasion of RASFs into the cartilage and strong perichondrocytic degradation ( Table 1) . To investigate whether viable chondrocytes are necessary for RASF migration toward human cartilage, we devitalized chondrocytes of the contralateral cartilage before implantation (Supplementary Fig. 1 ). We observed strong invasion and perichondrocytic degradation of RASFs into the chondrocytedepleted cartilage ( Table 1 and Fig. 2d) .
To assess whether human RASFs could migrate into ECM from other species, we implanted bovine or mouse cartilage together with human RASFs. We used bovine cartilage instead of human cartilage in the simultaneous coimplantation setting. In another approach, we implanted RASFs together with healthy mouse articular heads with scraped cartilage surface to expose the ECM, and, at the contralateral site, we implanted mouse articular scraped heads without RASFs ( Fig. 2g and Supplementary Fig. 1 ). We observed marked destruction of the bovine cartilage ( Table 1 and Fig. 2d ) and the matrix-exposed (scraped) mouse cartilage. Notably, RASF invasion was visible mainly at the cartilage-bone junction (Fig. 2g) .
Route of migration and influence of damaged cartilage
To elucidate the route of RASF migration from the primary implant to the contralateral implant, we analyzed the internal organs of 20 mice (from a variety of experimental settings) at day 60 after implantation ( Table 2) . In these mice, RASFs were applied either by direct coimplantation together with human cartilage (n = 5), implantation of RASFs together with human cartilage 14 d before or after Implantation of human cartilage together with RASFs and injection of TNF-α inhibitor (n = 13)
1.7 ± 0.8 1.5 ± 0.7
The mean values ± s.d. of all implants were calculated. Scoring was performed by five trained researchers. -, not evaluable (no viable chondrocytes); n, number of evaluated implants.
a r t i c l e s inserting the RASF-free cartilage (n = 2), by injection 14 d before or after implantation of the cartilage (i.v., s.c. or i.p., n = 4 each) or by direct coimplantation together with bovine cartilage (n = 1). We also detected the fluorescence of EGFP-transduced RASFs that were directly implanted together with human cartilage (n = 5). We were able to detect single human fibroblasts in the skin at the primary implantation site in one mouse out of 20 ( Fig. 3a) . In this mouse, RASFs were directly implanted together with human cartilage. We found the majority of RASFs in the spleen (Fig. 3b) . We also found single cells in the kidney and a lymph node in one mouse (Fig. 3a) . RASFs were not detectable in the intestine (Fig. 3c) , lung, heart, liver or skin distant from the implants (Fig. 3a) .
To evaluate whether RASFs are also able to migrate to mouse cartilage, we examined mouse auricular cartilage and joints by immunohistochemistry ( Table 2 ). In two out of 18 mice (11%), we detected human cells in healthy, untreated mouse joints (Fig. 3a) . The joints of two mice could not be evaluated, as the joints were damaged during the removal and cutting procedure. We found RASFs in the auricular cartilage in eight of 20 mice (40%) (Fig. 3a) . Six of these eight RASF-positive cartilage specimens showed single cells; the two remaining specimens had 10-50 human cells.
We used a collagenase-induced osteoarthritis mouse model 20 to analyze whether local cartilage damage leads to attachment and invasion of RASFs compared to healthy mouse joints. We administered collagenase to one healthy knee joint of the respective mice to damage the cartilage and subsequently injected human RASFs subcutaneously. After 28, 39, and 67 d, we examined treated and untreated joints for cartilage and bone erosions. Histological and immunohistological analyses showed invasive erosions into cartilage and bone in mice with injected RASFs in the collagenase-treated joints, which are untypical for the osteoarthritis mouse model, in contrast to control mice without RASFs at all time points (Fig. 3d and  Supplementary Fig. 2) .
To confirm the ability of RASFs to adhere to damaged cartilage matrix in vitro, we seeded OASFs and RASFs onto collagenase-treated and untreated mouse cartilage explants. OASFs did not attach to untreated cartilage, whereas RASFs showed a slight attachment to freshly isolated but untreated mouse cartilage (Fig. 3e) . Collagenase treatment of the cartilage considerably increased the attachment of synovial fibroblasts, with All organs were collected from 20 mice and used for the detection of RASFs (human cells) in the respective tissues. Organs evaluated were from animals directly coimplanted (n = 5), implanted at different time points (n = 2), injected (n = 4 subcutaneous, intraperitoneal, intravenous, each) or receiving bovine cartilage (n = 1). Of note, human cells could be detected in all spleens analyzed. The joints of two mice could not be evaluated and were excluded (n = 18). Single or few cells were detected next to the ear cartilage and the joints. -, not detectable. 
RASFs showing a markedly higher adhesion to the mouse cartilage (Fig. 3e) . To analyze whether RASFs are able to access the bloodstream and use this pathway for migration, we collected blood from 40 mice on the day of killing (60 d after implantation) and examined it by immunocytochemistry for the presence of human cells. For this experiment, we used mice that had been injected with RASFs (i.v., n = 13; s.c. n = 13; i.p., n = 14). The blood samples of 17 of these mice contained human RASFs. Of these RASF-positive mice, the cells were applied intravenously in ten mice, subcutaneously in four mice and intraperitoneally in three mice ( Fig. 3f and Supplementary Fig. 3) . We also analyzed blood from four mice in which RASFs had been directly coimplanted with cartilage. The blood samples from all of these four mice contained human RASFs 60 d after the implantation.
Additional PCR analysis of the Y chromosome gene SRY from RASFs from male human subjects implanted together with healthy cartilage from female human subjects into female SCID mice confirmed the presence of human cells circulating in the mouse blood samples (Fig. 3g) .
Migration and adhesion of RASFs in vitro
As RASFs have an increased potential to adhere to damaged cartilage matrix, we analyzed the expression of adhesion molecules by real-time PCR, after laser-mediated microdissection (LMM) of the invasion zone. Integrin subunits α 2 , α 4 , α ν , β 1 and β 5 were expressed at the sites of invasion (Fig. 3h) . We did not observe any difference between primary and contralateral implants. Noninvading cells in the surrounding sponge showed identical expression patterns (Fig. 3h) . The integrin subunits β 1 and β 5 were also strongly expressed in cultivated RASFs at the RNA and protein levels (data not shown). We confirmed the expression of the integrin subunit α ν by immunohistochemistry ( Supplementary Fig. 4) .
Transmigration through confluent cell layers is prerequisite for entering and leaving the bloodstream at sites of disease or to access distant locations. To investigate whether RASFs, similarly to tumor cells, are able to transmigrate, we used the transepithelial electrical resistance (TEER) assay to measure the breakdown of the electrical resistance generated by a monolayer of a clone of Madin-Darby canine kidney (MDCK-C7) cells as invasive cells transmigrate 21 . RASFs showed a strong transmigration through the monolayer comparable to Cal78 chondrosarcoma cells. Two days after adding RASFs onto MDCK-C7 cells, the resistance decreased to more than 60% of a r t i c l e s the baseline value (Fig. 4a) . Total breakdown was achieved after 3-4 d (Fig. 4a) . Human skin fibroblasts (HSFs) and OASFs did not show this invasive behavior (Fig. 4a) .
We blocked the cellular adhesion of RASFs with vascular cell adhesion molecule-1 (VCAM-1)-specific antibodies. After an adhesion time of 4 min, we observed a lower number of adhered RASFs compared to untreated RASFs (Fig. 4b) . Using the TEER assay, we analyzed the influence of BB-94 and tissue inhibitor of metalloproteinases-3 (TIMP-3) on the transmigration of RASFs. BB-94 is a broadspectrum hydroxamic acid-based zinc metalloproteinase inhibitor that inhibits both the matrix metalloproteinases (MMPs) and members of the ADAM family of enzymes. BB-94-treated or TIMP-3-transduced RASFs showed a lower transmigratory potential compared to the controls (Fig. 4c,d) . In vivo, application of tumor necrosis factor-α (TNF-α) inhibitors (40 mg per kg body weight every 10 or 14 d, i.p. or s.c.) did not result in a protective effect toward RASF migration and subsequent cartilage invasion in this migration model ( Table 1) .
DISCUSSION
Rheumatoid arthritis starts in a few joints but can spread to all joints during the course of the disease. This study addressed one of the remaining questions of rheumatoid arthritis: the mechanisms and effector cells that lead to this characteristic feature of progressive disease. We have shown that human RASFs are able to migrate long distances through the bloodstream in SCID mice and specifically migrate toward, attach to and invade into distant exposed cartilage matrix.
RASFs have the ability to remodel mesenchymal structures through the production of cytokines, chemokines, matrix components and MMPs 2, 3, 13, 15 . This remodeling ability has also been demonstrated in wound healing [15] [16] [17] [18] [19] , during which fibroblasts change from a 'resting' to an 'activated' phenotype 18 . In general, fibroblasts have a limited ability to migrate short distances, as fibroblasts are regarded as resident cells 15, 16, 21 . In our SCID mouse model, we observed RASFs undergoing the complex process of emigration from an affected joint (simulated by an RASF-containing cartilage complex), migration into a healthy joint (simulated by a RASF-free cartilage implant) and subsequent invasion of articular cartilage. These properties seem to be unique to RASFs, as OASFs neither invaded nor degraded human cartilage in vivo and OASFs and HSFs also lacked the transmigratory capacity in vitro.
Migration of RASFs does not seem to be dependent on active tissue damage or ongoing wound healing, as application of RASFs 14 d after implantation resulted in stronger cartilage destruction than if the RASFs were applied simultaneously. In contrast, advanced or completed wound healing and vascularization seem to promote RASF migration and adhesion to the implanted cartilage, independent of the route of RASF application. Our results suggest that RASF migration toward the cartilage takes place through the bloodstream. Cells migrating through the blood pass through the spleen, which is a major filter system of the circulation and is the only internal organ where we detected RASFs in all mice. Angiogenesis may be a feature promoting the invasion of RASFs into distant joints, as in our model we detected neovascularization of the implants as early as 7 d after implantation. This may have facilitated the early transmigration of RASFs from the blood into the implant.
Our data suggest that vital chondrocytes and chondrocyte-derived chemokines and other factors are not necessary for RASF migration and invasion. However, matrix components, small matrix fragments and other matrix-associated proteins in the ECM such as chemokines and growth factors may drive the migration of RASFs toward the accessible implanted cartilage, even in the absence of factors actively produced by chondrocytes [22] [23] [24] [25] [26] [27] [28] .
Expression of adhesion molecules such as VCAM-1 and integrins is increased in rheumatoid arthritis tissue [29] [30] [31] [32] [33] , and they may be crucial mediators of RASF transmigration into the vascular system and invasion into the cartilage. In our model, RASFs express integrins at sites of invasion.
Although we were able to show that RASFs are able to invade implanted bovine cartilage, we detected only a limited number of RASFs in healthy mouse joints or auricular cartilage of the SCID mice. A reason for the limited invasion into healthy joints may be the intact tissue structure. Invasion of RASFs into nonaffected joints most likely requires microlesions to initiate the attachment of RASFs to the matrix. This theory is in accordance with the observation of early erosions at the cartilage-bone junction in diseased individuals and the preference for disease manifestations in the dominant hand 34 . In the joint, the synovial lining layer is in close proximity and partially in direct contact with cartilage and bone [35] [36] [37] , similar to the situation in 
was prominent at cartilage-bone junctions. Our finding of erosions similar to human rheumatoid arthritis, and untypical of osteoarthritis, when we injected RASFs into mice treated with collagenase (a model of osteoarthritis) also suggests that damage is required for invasion. Taken together, these results support the idea that RASFs are one of the key pathophysiological factors that facilitate and drive the progression from oligo-to polyarticular disease in rheumatoid arthritis, and that this is based on the unique potential of the RASFs to migrate via the vasculature toward hitherto unaffected cartilage.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
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Tissues and cells. We obtained rheumatoid arthritis (n = 17) and osteoarthritis (n = 6) synovial tissues during arthroplastic surgery (approved by the Ethics Committee Universities of Giessen and Muenster). The subjects gave informed consent and fulfilled the criteria of the American College of Rheumatology 38 . We isolated and cultured RASFs (n = 14) and OASFs (n = 6) from various subjects (maximum five passages) 12, 39, 40 . Human skin fibroblasts (HSFs) were obtained during trauma surgery of healthy subjects (approved by the Ethics Committee University of Muenster; the subjects gave informed consent).
We obtained healthy human cartilage (n = 38) from nonarthritic knee joints and obtained complete arthritic synovial tissue (n = 3) on the day of implantation (approved by the Ethics Committee University of Giessen; the subjects gave informed consent). We received healthy bovine joints from a butchery and obtained the Cal78 chondrosarcoma cell line from DSMZ (German Collection of Microorganisms and Cell Cultures, 'Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH').
Mice. We housed female 5-week-old Crl-scidBR and wild-type mice (Charles River) under germ-free conditions. Experiments were approved by the Animal Care and Use Committee of Hesse.
Adenoviral transduction.
We inserted a cDNA encoding EGFP into replicationdeficient type 5 adenoviruses (∆E1/E3) 41 under control of a cytomegalovirus promoter. We added a multiplicity of infection of 30 to 5 × 10 5 RASFs, incubated them (37 °C, 2 h), washed them and cultured them until implantation 12 . The infection rate was 95%, with decreasing EGFP expression (day 60: 10-25%). Adenovirally transduced RASFs were used to detect human cells in murine organs.
Severe combined immunodeficient mouse model. We prepared the spongecartilage complex with or without human cells and implanted it with the inverse wrap technique under the skin of the SCID mice as described previously 42 . Alternatively, we implanted bovine cartilage or healthy articular heads with scraped surface of shoulders or hips from donor mice or devitalized cartilage 43 . We inserted one sponge including cartilage and fibroblasts subcutaneously into a SCID mouse (primary) and another cell-free cartilage-sponge complex contralaterally (Fig. 1a) . We found no difference in invasion between gelatin sponges and plasticpolymer sponges (data not shown). If not indicated otherwise, we used gelatin sponges for the implantation into SCID mice. In additional experimental settings, we implanted synovial tissue at the primary site and simultaneously human cartilage was inserted at the contralateral site. Furthermore, time-displaced implantation of primary and contralateral implants was performed (14 d), or the RASFs were injected i.v., s.c. or i.p 14 d after or before implantation of the RASF-free cartilage complex.
After 60 d, we killed the mice for all experimental settings, if not mentioned otherwise. We collected blood and removed implants, organs and implanted articular heads. We decalcified articular heads and joints and embedded them in paraffin. We snap-froze all other tissues. We analyzed early neovascularization at days 7 and 14 after implantation.
We evaluated implants in stained sections to determine fibroblast invasion and perichondrocytic cartilage degradation 11, 14, 39, 44 . We classified invasion scores as follows: no or minimal invasion, 0; visible invasion (two cell depths), 1; invasion (five cell depths), 2; deep invasion (more than ten cell depths), 3. We classified perichondrocytic cartilage degradation scores as follows: no degradation (sharp, intact halo of the chondrons compared with the cartilage stored before implantation), 0; visible degradation (one diameter of the chondron), 1; degradation (between one and two diameters of a chondron), 2; intensive degradation (more than two diameters of a chondron), 3. All single implants from all mice were scored by five different trained researchers.
We detected human RASFs in mice by analyzing the organs of 20 mice. We applied RASFs either by direct coimplantation (n = 5), implantation at various time points (n = 2), by injection (i.v., s.c., i.p., n = 4 each) or by implantation of bovine cartilage (n = 1).
We collected blood samples from 40 mice on the day of killing (60 d after implantation). We used mice from the injection groups (i.v., n = 13; s.c., n = 13; i.p., n = 14) for immunocytochemistry. As a control, we analyzed blood from directly coimplanted mice (n = 4).
Application of tumor necrosis factor-α inhibitors in the SCID mouse model. As a therapeutic approach, we injected the TNF-α inhibitor adalimumab (40 mg per kg body weight, Abbott Laboratories) s.c. or i.p. every 14 or 10 d, respectively. We removed implants 60 d after implantation.
Collagenase injection into mouse joints. To show a potential RASF migration into damaged murine joints in comparison to healthy joints, we injected collagenase (5 U; Sigma) intra-articularily in one knee 20 and applied RASFs s.c. at the day of collagenase injection. After 28, 39 and 67 d, we removed the injected as well as the noninjected control joints and embedded them in paraffin followed by immunohistological and histological evaluation using standard Giemsa or H&E staining.
Immunohistochemistry. Antibodies for frozen sections were as follows: mouse antibody to human vimentin (1 in 100; M7020, Dako); mouse antibody to human follistatin (1 in 100; MAB669, R&D Systems); goat antibody to human proMMP-13 (1 in 100; AF511; R&D Systems); mouse antibody to human integrin α ν (1 in 100; MAB1953Z, Chemicon); mouse antibody to mouse H-2D d (1 in 50; 553577; BD Biosciences) and goat antibody to mouse IL-1 receptor (1 in 25; AF771, R&D Systems). Detection was performed with Histofine Simple-Stain MAX/PO mouse-specific, rabbit-specific or goat-specific detection system (Medac) or secondary antibodies (BD Biosciences) and 3-amino-9-ethylcarbazole substrate (Vector Laboratories).
We did immunohistochemistry using paraffin sections with antibodies against human vimentin and mouse H-2D d after proteinase K demasking. We used rheumatoid arthritis synovium as positive control. Staining was performed as described above.
After erythrocyte lysis (Qiagen), we collected blood cells onto slides using a cytospin centrifuge, fixed them and analyzed them immunocytochemically.
Laser-mediated microdissection. We performed LMM with a Robot-MicroBeam laser microscope (P.A.L.M. Microlaser Technologies) [45] [46] [47] and extracted RNA from 10,000 cartilage-invading cells (PicoPure RNA Isolation Kit).
PCR.
We implanted RASFs from male subjects along with female human cartilage. We isolated the DNA from mouse blood (QIAamp DNA Blood Kit, QIAGEN) and concentrated it (Microcon, Millipore). We performed a standard amplification (50 °C annealing temperature, T a ) and then purified and reamplified the DNA. Human male and female DNA, as well as distilled water served as controls. Primers used for amplification of human SRY were 5′-GCGTATTCAA CAGCGATGATTACAG-3′ and 5′-GTTACCCGATTGTCCTACAGCTTTG-3′.
For real-time PCR, we synthesized cDNA to analyze integrin expression after LMM (LightCycler, Roche) 45 . Porphobilinogen deaminase served as endogenous control. Primers used for integrin α 2 were 5′-AGAAGTCTGTTGCCTGCGAT-3′ and 5′-CTTGGAAACTGAGAGACGCC-3′ with a T a of 50 °C; for integrin-α 4 5′-AAATGGATGGCCTTCTGTG-3′ and 5′-TCTTGGTGGAGACTCTGCCT-3′, T a 48 °C; for integrin β 1 5′-ATCCCAGAGGCTCCAAAGAT-3′ and 5′-CC CCTGATCTTAATCGCAAA-3′, T a 50 °C; for integrin β 5 5′-TGCCTTGCTT GGAGAGAAAT-3′ and 5′-AATCTCCACCGTTGTTCCAG-3′, T a 50 °C.
Transepithelial electrical resistance assay and endothelial attachment assay. We added 800,000 cells onto a MDCK-C7 monolayer 21 and determined cellular invasion in quadruplicate through TEER until total breakdown. We performed treatment approaches using 100 ng ml −1 BB-94 (British Biotech, Oxford, UK) in comparison to untreated controls (untreated RASFs, n = 2; RASFs with BB-94, n = 2; primary culture from one subject). In a second approach, we used a nonviral expression construct (pFlagCMV-2) encoding TIMP-3 10 h after lipofection (Lipofectamine 2000; Invitrogen) in comparison to untreated and mock-transfected RASFs (untreated RASFs, n = 2; mock, n = 4; TIMP-3, n = 4; primary culture from two subjects).
To determine the attachment of RASF to endothelial cells, we placed human umbilical vein endothelial cells on gelatin-coated glass coverslips on a microchip (microfluidic device, 146 MHz, 1 dBm) to generate a laminar flow. We added 3,000 stained RASFs and quantified the attached RASFs after 4 min. Treatment approaches using VCAM-1-specific antibodies (50 ng ml −1 , 2 h; Abcam) were performed in comparison to untreated controls (VCAM-1-specific antibodies n = 3, control n = 4; primary culture from one subject).
Cartilage attachment assay. We isolated mouse femoral head cartilage 48 and cultured it in DMEM at 37 °C, 5% CO 2 for 24 h. We placed RASFs and OASFs 49 on proteoglycan-reduced cartilage (0.25 mg ml −1 collagenase, 4 h) 50 for 2 h under rotation, cultured them for 12 h, fixed them and quantified the attached cells.
Statistical analyses.
We used the t test for statistical analysis for parametric data and the Mann-Whitney test for nonparametric data. We considered P values below 0.05 significant.
